Literature DB >> 23478619

Technical and functional results of the artificial bowel sphincter for treatment of severe fecal incontinence: is there any benefit for the patient?

Benjamin Darnis1, Jean-Luc Faucheron, Henri Damon, Xavier Barth.   

Abstract

BACKGROUND: Fecal incontinence is a socially devastating problem that can be cured by the artificial bowel sphincter in selected cases.
OBJECTIVE: This study evaluates short- and long-term morbidity and functional results of the artificial bowel sphincter.
DESIGN: This study is a retrospective evaluation of consecutive patients. SETTINGS: This study was conducted at 2 academic colorectal units. PATIENTS: Between May 2003 and July 2010, all consecutive patients who underwent artificial bowel sphincter implantation for severe fecal incontinence were included in the study. INTERVENTION: The artificial bowel sphincter was implanted through 2 incisions made in the perineum and suprapubic area. MAIN OUTCOME MEASURES: Patients were reviewed at months 1, 6, and 12, and then annually. Mortality, morbidity (early infection within the first 30 days after implant, and late thereafter), and reoperations including explantations were analyzed. Anal continence was evaluated by means of the Cleveland Clinic Florida score. Mean follow-up was 38 months (range, 12-98).
RESULTS: Between May 2003 and July 2010, 21 consecutive patients with a mean age of 51 years (range, 23-71) underwent surgery. There was no mortality. All patients presented with at least 1 complication. Infection or cutaneous ulceration occurred in 76% of patients, perineal pain in 29%, and rectal evacuation disorders in 38%. The artificial bowel sphincter was definitely explanted from 17 patients (81%). The artificial sphincter was able to be activated in 17 patients (81%), and continence was satisfactory at 1 year in those who still had their sphincter in place (n = 12).
CONCLUSION: There is a very high rate of morbidity and explantation after implantation of an artificial bowel sphincter for fecal incontinence. Four of 21 patients who still had an artificial sphincter in place had satisfactory continence at a mean follow-up of 38 months.

Entities:  

Mesh:

Year:  2013        PMID: 23478619     DOI: 10.1097/DCR.0b013e3182809490

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

1.  Sacral neuromodulation for bowel dysfunction.

Authors:  J-L Faucheron; G Martin
Journal:  Tech Coloproctol       Date:  2013-06-06       Impact factor: 3.781

2.  Erosion Rate of the Magnetic Sphincter Augmentation Device Is Much Higher for Anal Incontinence than for Antireflux.

Authors:  Jean-Luc Faucheron; Pierre-Yves Sage; Bertrand Trilling
Journal:  J Gastrointest Surg       Date:  2018-11-07       Impact factor: 3.452

Review 3.  Faecal incontinence: Current knowledges and perspectives.

Authors:  Alban Benezech; Michel Bouvier; Véronique Vitton
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

4.  Clinical Challenges of Fecal Incontinence in the Elderly.

Authors:  Hadie Razjouyan; Shanti Prasad; Sita Chokhavatia
Journal:  Curr Treat Options Gastroenterol       Date:  2015-09

Review 5.  What's New in the Toolbox for Constipation and Fecal Incontinence?

Authors:  Yeong Yeh Lee
Journal:  Front Med (Lausanne)       Date:  2014-03-24

6.  Combined application of chondroitinase ABC and photobiomodulation with low-intensity laser on the anal sphincter repair in rabbit.

Authors:  Arash Sarveazad; Abazar Yari; Arash Babaei-Ghazani; Marjan Mokhtare; Mansour Bahardoust; Siavash Asar; Jebreil Shamseddin; Mahmoud Yousefifard; Asrin Babahajian
Journal:  BMC Gastroenterol       Date:  2021-12-15       Impact factor: 3.067

Review 7.  Current and emerging treatment options for fecal incontinence.

Authors:  Satish S C Rao
Journal:  J Clin Gastroenterol       Date:  2014-10       Impact factor: 3.062

8.  Successful Treatment of Passive Fecal Incontinence in an Animal Model Using Engineered Biosphincters: A 3-Month Follow-Up Study.

Authors:  Jaime L Bohl; Elie Zakhem; Khalil N Bitar
Journal:  Stem Cells Transl Med       Date:  2017-07-05       Impact factor: 6.940

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.